PAR-4: a possible new target for age-related disease

Bibliography

• Vejux A, Lizard G. Cytotoxic effects of oxysterols associated with human diseases: induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. Mol Aspects Med 2009;30(3):153-70
   PubMed Web of Science ®Google Scholar
• Campisi J, Sedivy J. How does proliferative homeostasis change with age? What causes it and how does it contribute to aging? J Gerontol A Biol Sci Med Sci 2009;64(2):164-6
   PubMed Web of Science ®Google Scholar
• Hebbar N, Wang C, Rangnekar VM. Mechanisms of apoptosis by the tumor suppressor PAR-4. J Cell Physiol 2012;227(12):3715-21
   PubMed Web of Science ®Google Scholar
• Burikhanov R, Zhao Y, Goswami A, et al. PAR-4 activates an extrinsic pathway for apoptosis. Cell 2009;138(2):377-88
   PubMed Web of Science ®Google Scholar
• Zhao Y, Burikhanov R, Qiu S, et al. Cancer resistance in transgenic mice expressing the SAC module of PAR-4. Cancer Res 2007;67(19):9276-85
   PubMed Web of Science ®Google Scholar
• Gurumurthy S, Goswami A, Vasudevan KM, et al. Phosphorylation of PAR-4 by protein kinase a is critical for apoptosis. Mol Cell Biol 2005;25(3):1146-61
   PubMed Web of Science ®Google Scholar
• Chaudhry P, Singh M, Parent S, et al. Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation. Mol Cell Biol 2012;32(4):826-39
   PubMed Web of Science ®Google Scholar
• Shrestha-Bhattarai T, Rangnekar VM. Cancer-selective apoptotic effects of extracellular and intracellular PAR-4. Oncogene 2010;29(27):3873-80
   PubMed Web of Science ®Google Scholar
• Burikhanov R, Shrestha-Bhattarai T, Qiu S, et al. Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4. Cancer Res 2013;73(2):1011-19
   PubMed Web of Science ®Google Scholar
• Burikhanov R, Shrestha-Bhattarai T, Hebbar N, et al. Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Rep 2014;6(2):271-7
   PubMed Web of Science ®Google Scholar
• Glienke W, Chow KU, Bauer N, et al. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 2006;47:1629-38
   PubMed Web of Science ®Google Scholar
• Zhang L, Guo L, Peng Y, et al. Expression of T-STAR gene is associated with regulation of telomerase activity in human colon cancer cell line HCT-116. World J Gastroenterol 2006;12:4056-60
   PubMed Web of Science ®Google Scholar
• Zhou L, Chen B, Hua X, et al. Effect of newly identified hTERT-interacting proteins on telomerase activity. Acta Biochim Biophys Sin (Shanghai) 2013;45(8):674-82
   PubMed Web of Science ®Google Scholar
• Sheng JF, Chen W, Yu Y, et al. PAR-4 and hTERT expression are negatively correlated after RNA interference targeting hTERT in laryngocarcinoma cells. Tissue Cell 2010;42(6):365-9
   PubMed Web of Science ®Google Scholar
• Culmsee C, Zhu Y, Krieglstein J, Mattson MP. Evidence for the involvement of PAR-4 in ischemic neuron cell death. J Cereb Blood Flow Metab 2001;21(4):334-43
   PubMed Web of Science ®Google Scholar
• Mattson MP, Duan W, Pedersen WA, et al. Neurodegenerative disorders and ischemic brain diseases. Apoptosis 2001;6(1-2):69-81
   PubMed Web of Science ®Google Scholar
• Mattson MP, Pedersen WA, Duan W, et al. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer’s and Parkinson’s diseases. Ann N Y Acad Sci 1999;893:154-75
   PubMed Web of Science ®Google Scholar
• Xie J, Guo Q. PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. J Biol Chem 2005;280(14):13824-32
   PubMed Web of Science ®Google Scholar
• Feng Z, Qin C, Chang Y, Zhang JT. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer’s disease. Free Radic Biol Med 2006;40(1):101-9
   PubMed Web of Science ®Google Scholar
• Duan W, Zhang Z, Gash DM, et al. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson’s disease. Ann Neurol 1999;46(4):587-97
   PubMed Web of Science ®Google Scholar
• Eberhardt O, Schulz JB. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson’s disease. Toxicol Lett 2003;139(2-3):135-51
   PubMed Web of Science ®Google Scholar
• Moos T, Jensen PH. Absence of prostate apoptosis response-4 protein in substantia nigra of Parkinson’s disease autopsies. Acta Neuropathol 2004;107(1):23-6
   PubMed Web of Science ®Google Scholar
• Fukunaga K, Shioda N. Novel dopamine D2 receptor signaling through proteins interacting with the third cytoplasmic loop. Mol Neurobiol 2012;45(1):144-52
   PubMed Web of Science ®Google Scholar
• Pedersen WA, Luo H, Kruman I, et al. The prostate apoptosis response-4 protein participates in motor neuron degeneration in amyotrophic lateral sclerosis. FASEB J 2000;14(7):913-24
   PubMed Web of Science ®Google Scholar
• Xie J, Awad KS, Guo Q. RNAi knockdown of PAR-4 inhibits neurosynaptic degeneration in ALS-linked mice. J Neurochem 2005;92(1):59-71
   PubMed Web of Science ®Google Scholar
• Hwang S, Moon M, Kim S, et al. Neuroprotective effect of ghrelin is associated with decreased expression of prostate apoptosisresponse-4. Endocr J 2009;56(4):609-17
   PubMed Web of Science ®Google Scholar
• Chung H, Seo S, Moon M, et al. IGF-I inhibition of apoptosis is associated with decreased expression of prostate apoptosisresponse-4. J Endocrinol 2007;194(1):77-85
   PubMed Web of Science ®Google Scholar
• Payette DJ, Xie J, Shirwany N, et al. Exacerbation of apoptosis of cortical neurons following traumatic brain injury in PAR-4 transgenic mice. Int J Clin Exp Pathol 2008;1(1):44-56
   PubMed Web of Science ®Google Scholar
• Zhu X, Peng S, Zhang S, et al. Stress-induced depressive behaviors are correlated with PAR-4 and DRD2 expression in rat striatum. Behav Brain Res 2011;223(2):329-35
   PubMed Web of Science ®Google Scholar
• Wang LH, Chen JY, Liou YJ, et al. Association of missense variants of the PRKC, apoptosis, WT1, regulator (PAWR) gene with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(3):870-5
   PubMed Web of Science ®Google Scholar
• Amar S, Shaltiel G, Mann L, et al. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology ofschizophrenia. Int J Neuropsychopharmacol 2008;11(2):197-205
   PubMed Web of Science ®Google Scholar
• Glantz LA, Gilmore JH, Overstreet DH, et al. Pro-apoptotic PAR-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res 2010;118(1-3):292-9
   PubMed Web of Science ®Google Scholar
• Chetcuti A, Adams LJ, Mitchell PB, et al. Altered gene expression in mice treated with the mood stabilizer sodium valproate. Int J Neuropsychopharmacol 2006;9(3):267-76
   PubMed Web of Science ®Google Scholar
• Liou YJ, Chen ML, Wang YC, et al. Analysis of genetic variations in the human PAR-4 (PAWR) gene and tardive dyskinesia in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2009;150B(3):439-40
   PubMed Web of Science ®Google Scholar
• Kishi T, Ikeda M, Kitajima T, et al. No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population. Am J Med Genet B Neuropsychiatr Genet 2008;147B(4):531-4
   PubMed Web of Science ®Google Scholar
• Kim IS, Yoon HK, Kang SG, et al. No association between PAWR gene polymorphisms and tardive dyskinesia in schizophreniapatients. Psychiatry Investig 2012;9(2):191-4
   PubMed Web of Science ®Google Scholar
• Pandol S, Gukovskaya A, Edderkaoui M, et al. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol 2012;27(Suppl 2):127-34
   PubMed Web of Science ®Google Scholar
• Perez-Mancera PA, Tuveson DA. Physiological analysis of oncogenic K-ras. Methods Enzymol 2006;407:676-90
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Tuveson DA. In search of an early warning system for pancreatic cancer. Cancer Biol Ther 2003;2(1):84-6
   PubMed Web of Science ®Google Scholar
• Jonson T, Albrechtsson E, Axelson J, et al. Alteredexpression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas. Int J Oncol 2001;19(1):71-81
   PubMed Web of Science ®Google Scholar
• Jonson T, Gorunova L, Dawiskiba S, et al. Molecular analysesof the 15q and 18q SMAD genes in pancreatic cancer. Genes Chromosomes Cancer 1999;24(1):62-71
   PubMed Web of Science ®Google Scholar
• Truty MJ, Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology 2007;7(5-6):423-35
   PubMed Web of Science ®Google Scholar
• Truty MJ, Urrutia R. Transforming growth factor-beta: what every pancreatic surgeon should know. Surgery 2007;141(1):1-6
   PubMed Web of Science ®Google Scholar
• Ahmed MM, Sheldon D, Fruitwala MA, et al. Downregulationof PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int J Cancer 2008;122(1):63-70
   PubMed Web of Science ®Google Scholar
• Boucher MJ, Morisset J, Vachon PH, et al. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000;79(3):355-69
   PubMed Web of Science ®Google Scholar
• Greten FR, Weber CK, Greten TF, et al. Stat3 and NF-kappa B activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002;123(6):2052-63
   PubMed Web of Science ®Google Scholar
• Azmi AS, Wang Z, Burikhanov R, et al. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther 2008;7(9):2884-93
   PubMed Web of Science ®Google Scholar
• Azmi AS, Ahmad A, Banerjee S, et al. Chemoprevention ofpancreatic cancer: characterization of PAR-4 and its modulation by 3,3’ diindolylmethane (DIM). Pharm Res 2008;25(9):2117-24
   PubMed Web of Science ®Google Scholar
• Azmi AS, Philip PA, Zafar SF, et al. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets 2010;14(6):611-20
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8(1):27-36
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30
   PubMed Web of Science ®Google Scholar
• Nagai MA, Gerhard R, Salaorni S, et al. Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol 2010;37(1):41-9
   PubMed Web of Science ®Google Scholar
• De Bessa Garcia SA, Pereira MC, Nagai MA. Expression pattern of the pro-apoptotic gene PAR-4 during the morphogenesis of MCF-10A human mammary epithelial cells. Cancer Microenviron 2010;4(1):33-8
   PubMedGoogle Scholar
• Zapata-Benavides P, Méndez-Vázquez JL, González-Rocha TR, et al. Expression of prostate apoptosis response (PAR-4) is associated with progesterone receptor in breast cancer. Arch Med Res 2009;40(7):595-9
   PubMed Web of Science ®Google Scholar
• Méndez-López LF, Zapata-Benavides P, Zavala-Pompa A, et al. Immunohistochemical analysis of prostate apoptosis response-4 (PAR-4) in Mexican women with breast cancer: a preliminary study. Arch Med Res 2010;41(4):261-8
   PubMed Web of Science ®Google Scholar
• Casolari DA, Pereira MC, de Bessa Garcia SA, et al. Insulin-like growth factor-1 and 17 beta-estradiol down-regulate prostate apoptosis response-4 expression in MCF-7 breast cancer cells. Int J Mol Med 2011;28(3):337-42
   PubMed Web of Science ®Google Scholar
• Pereira MC, de Bessa-Garcia SA, Burikhanov R, et al. Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells. Int J Oncol 2013;43(2):531-8
   PubMed Web of Science ®Google Scholar
• Alvarez JV, Pan TC, Ruth J, et al. PAR-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy. Cancer Cell 2013;24(1):30-44
   PubMed Web of Science ®Google Scholar
• Shrestha-Bhattarai T, Hebbar N, Rangnekar VM. Par(-4)oxysm in breast cancer. Cancer Cell 2013;24(1):3-5
   PubMed Web of Science ®Google Scholar
• Ohki R, Yamamoto K, Mano H, et al. Identification of mechanically induced genes in human monocytic cells by DNA microarrays. J Hypertens 2002;20(4):685-91
   PubMed Web of Science ®Google Scholar
• Verdejo HE, del Campo A, Troncoso R, et al. Mitochondria, myocardial remodeling, and cardiovascular disease. Curr Hypertens Rep 2012;14(6):532-9
   PubMed Web of Science ®Google Scholar
• Luoma PV. Elimination of endoplasmic reticulum stress and cardiovascular, type 2 diabetic, and other metabolic diseases. Ann Med 2013;45(2):194-202
   PubMed Web of Science ®Google Scholar
• MacDonald JA, Moffat LD, Al-Ghabkari A, et al. Prostate-apoptosis response-4 phosphorylation in vascular smooth muscle. Arch Biochem Biophys 2013;535(1):84-90
   PubMed Web of Science ®Google Scholar
• Bojarska-Junak A, Sieklucka M, Hus I, et al. Assessment of the pathway of apoptosis involving PAR-4, DAXX and ZIPK proteins in CLL patients and its relationship with the principal prognostic factors. Folia Histochem Cytobiol 2011;49(1):98-103
   PubMed Web of Science ®Google Scholar
• Vetterkind S, Lee E, Sundberg E, et al. PAR-4: a new activator of myosin phosphatase. Mol Biol Cell 2010;21(7):1214-24
   PubMed Web of Science ®Google Scholar
• Boosen M, Vetterkind S, Kubicek J, et al. PAR-4 is an essential downstream target of DAP-like kinase (Dlk) in Dlk/PAR-4-mediated apoptosis. Mol Biol Cell 2009;20(18):4010-20
   PubMed Web of Science ®Google Scholar
• Vetterkind S, Morgan KG. The pro-apoptotic protein PAR-4facilitates vascular contractility by cytoskeletal targeting of ZIPK. J Cell Mol Med 2009;13(5):887-95
   PubMed Web of Science ®Google Scholar
• Shoval Y, Pietrokovski S, Kimchi A. ZIPK: a unique case of murine-specific divergence of a conserved vertebrate gene. PLoS Genet 2007;3(10):1884-93
   PubMed Web of Science ®Google Scholar
• Young MJ. Targeting the mineralocorticoid receptor in cardiovasculardisease. Expert Opin Ther Targets 2013;17(3):321-31
   PubMed Web of Science ®Google Scholar
• Marti CN, Gheorghiade M, Kalogeropoulos AP, et al. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 2012;60(16):1455-69
   PubMed Web of Science ®Google Scholar
• Xie J, Guo Q. PAR-4 is a novel mediator of renaltubule cell death in models of ischemia-reperfusion injury. Am J Physiol Renal Physiol 2007;292(1):F107-15
   PubMed Web of Science ®Google Scholar
• Sun B, Lu C, Zhou GP, et al. Suppression of PAR-4 protects human renal proximal tubule cells from apoptosis induced by oxidative stress. Nephron Exp Nephrol 2011;117(3):e53-61
   PubMedGoogle Scholar
• Bensellam M, Laybutt DR, Jonas JC. The molecular mechanisms of pancreatic beta-cell glucotoxicity: recent findings and future research directions. Mol Cell Endocrinol 2012;364(1-2):1-27
   PubMed Web of Science ®Google Scholar
• Nyalakonda K, Sharma T, Ismail-Beigi F. Preservation of beta-cell function in type 2 diabetes. Endocr Pract 2010;16(6):1038-55
   PubMed Web of Science ®Google Scholar
• O’Sullivan ES, Vegas A, Anderson DG, et al. Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain. Endocr Rev 2011;32(6):827-44
   PubMed Web of Science ®Google Scholar
• Leibowitz G, Kaiser N, Cerasi E. Balancing needs and means: the dilemma of the beta-cell in the modern world. Diabetes Obes Metab 2009;11(Suppl 4):1-9
   PubMedGoogle Scholar
• Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52(1):102-10
   PubMed Web of Science ®Google Scholar
• Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005;307(5708):380-4
   PubMed Web of Science ®Google Scholar
• Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011;334(6059):1081-6
   PubMed Web of Science ®Google Scholar
• Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306(5695):457-61
   PubMed Web of Science ®Google Scholar
• Gorman AM, Healy SJ, Jäger R, et al. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther 2012;134(3):306-16
   PubMed Web of Science ®Google Scholar
• Shirakawa J, Togashi Y, Sakamoto E, et al. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta cells. Diabetes 2013;62(10):3448-58
   PubMed Web of Science ®Google Scholar
• Araki E, Oyadomari S, Mori M. Impact of endoplasmic reticulum stress pathway on pancreatic beta-cells and diabetes mellitus. Exp Biol Med (Maywood) 2003;228(10):1213-17
   PubMed Web of Science ®Google Scholar
• Oyadomari S, Koizumi A, Takeda K, et al. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest 2002;109(4):525-32
   PubMed Web of Science ®Google Scholar
• Itkin-Ansari P, Levine F. Sources of beta-cells for human cell-based therapies for diabetes. Cell Biochem Biophys 2004;40(3 Suppl):103-12
   PubMedGoogle Scholar
• Wu HL, Wang Y, Zhang P, et al. Reversible immortalization of rat pancreatic beta cells with a novel immortalizing and tamoxifen-mediated self-recombination tricistronic vector. J Biotechnol 2011;151(3):231-41
   PubMed Web of Science ®Google Scholar
• Ravassard P, Hazhouz Y, Pechberty S, et al. A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion. J Clin Invest 2011;121(9):3589-97
   PubMed Web of Science ®Google Scholar
• Chaudhry P, Fabi F, Singh M, et al. Prostate apoptosis response-4 mediates TGF-beta-induced epithelial-to-mesenchymal transition. Cell Death Dis 2014;5:e1044
   PubMed Web of Science ®Google Scholar
• Zhao Y, Burikhanov R, Brandon J, et al. Systemic Par-4 inhibits non-autochthonous tumor growth. Cancer Biol Ther 2011;12(2):152-7
   PubMed Web of Science ®Google Scholar